Patents Assigned to The Salk Institute for Biological Studies
  • Patent number: 9938234
    Abstract: Provided herein are compounds and compositions useful in increasing PPAR? activity. The compounds and compositions provided herein are useful for the treatment of PPAR? related diseases (e.g., muscular diseases, vascular disease, demyelinating disease, and metabolic diseases).
    Type: Grant
    Filed: October 2, 2015
    Date of Patent: April 10, 2018
    Assignees: Salk Institute for Biological Studies, Mitobridge, Inc.
    Inventors: Ronald M. Evans, Michael Downes, Thomas J. Baiga, Joseph P. Noel, Emi Kanakubo Embler, Weiwei Fan, John F. W. Keana, Mark G. Bock, Arthur F. Kluge, Mike A. Patane
  • Patent number: 9925243
    Abstract: The present disclosure provides chimeric proteins having an N-terminus coupled to a C-terminus, wherein the N-terminus comprises an N-terminal portion of fibroblast growth factor (FGF) 2 and the C-terminus comprises a portion of an FGF1 protein, wherein the chimeric protein comprises at least 95% sequence identity to SEQ ID NO: 9, 10, 11, 12 or 13. Also provided are nucleic acid molecules that encode such proteins, and vectors and cells that include such nucleic acids. Methods of using the disclosed molecules to reduce blood glucose levels are also provided.
    Type: Grant
    Filed: April 6, 2016
    Date of Patent: March 27, 2018
    Assignee: Salk Institute for Biological Studies
    Inventors: Jae Myoung Suh, Michael Downes, Ronald M. Evans, Annette Atkins, Senyon Choe, Witek Kwiatkowski
  • Patent number: 9925241
    Abstract: The present disclosure provides FGF1 mutant proteins, such as those having an N-terminal deletion, point mutation(s), or combinations thereof, which can reduce blood glucose in a mammal. Such mutant FGF1 proteins can be part of a chimeric protein that includes a ?-Klotho-binding protein, an FGFR1c-binding protein, a ?-Klotho-binding protein and a FGFR1c-binding protein, a C-terminal region from FGF19 or FGF21. In some examples, mutant FGF1 proteins have reduced mitogenic activity. Also provided are nucleic acid molecules that encode such proteins, and vectors and cells that include such nucleic acids. Methods of using the disclosed molecules to reduce blood glucose levels are also provided.
    Type: Grant
    Filed: October 21, 2014
    Date of Patent: March 27, 2018
    Assignee: Salk Institute for Biological Studies
    Inventors: Jae Myoung Suh, Michael Downes, Ronald M. Evans, Annette Atkins, Ruth T. Yu
  • Publication number: 20180071318
    Abstract: The present disclosure provides compositions that include a nanoparticle and a compound that increases the biological activity of the vitamin D receptor (VDR) (e.g., a VDR agonist), and methods of using such compounds to increase retention or storage of vitamin A, vitamin D, and/or lipids by a cell, such as an epithelial or stellate cell. Such methods can be used to treat or prevent fibrosis.
    Type: Application
    Filed: November 8, 2017
    Publication date: March 15, 2018
    Applicants: Salk Institute for Biological Studies, The University of Sydney
    Inventors: Ning Ding, Michael Downes, Christopher Liddle, Ronald M. Evans
  • Patent number: 9913866
    Abstract: Compositions and methods for retargeting adenovirus to a cell using chemical dimers are described. In particular, a recombinant adenovirus comprising a nucleic acid comprising a capsid-dimerizing agent binder conjugate and a ligand-dimerizing agent binder conjugate is provided.
    Type: Grant
    Filed: September 12, 2014
    Date of Patent: March 13, 2018
    Assignee: Salk Institute for Biological Studies
    Inventors: Clodagh O'Shea, Shigeki Miyake-Stoner, Colin Powers
  • Publication number: 20180057554
    Abstract: The present disclosure provides FGF1 mutant proteins, which include an N-terminal deletion, point mutation(s), or combinations thereof. In some examples, the mutant FGF1 proteins have reduced mitogenic activity. Also provided are nucleic acid molecules that encode such proteins, and vectors and cells that include such nucleic acids. The disclosed FGF1 mutants can reduce blood glucose in a mammal, and in some examples are used to treat a metabolic disorder.
    Type: Application
    Filed: October 16, 2017
    Publication date: March 1, 2018
    Applicant: Salk Institute for Biological Studies
    Inventors: Ronald M. Evans, Michael Downes, Annette Atkins, Ruth T. Yu
  • Publication number: 20180050087
    Abstract: Provided herein are methods and compositions for treating lipodystrophy using fibroblast growth factor 1 (FGF-1) compounds.
    Type: Application
    Filed: October 6, 2017
    Publication date: February 22, 2018
    Applicants: Salk Institute for Biological Studies, Metacrine, Inc.
    Inventors: Neil McDonnell, Ronald M. Evans, Michael Downes
  • Patent number: 9895381
    Abstract: Provided herein are methods of treating and preventing pancreatitis, such as pancreatitis induced by glucagon-like peptide (GLP) agonists (such as GLP-1 agonists, for example Byetta®), by administration of a vitamin D receptor agonist (such as vitamin D, vitamin D analogs, vitamin D precursors, and vitamin D receptor agonists precursors). In some examples the subject has diabetes, such as type 2 diabetes.
    Type: Grant
    Filed: December 4, 2015
    Date of Patent: February 20, 2018
    Assignee: Salk Institute for Biological Studies
    Inventors: Mara Sherman, Michael Downes, Ronald M. Evans
  • Publication number: 20180044642
    Abstract: The invention generally features compositions comprising induced pluripotent stem cell progenitors (also termed reprogramming progenitor cells) and methods of isolating such cells. The invention also provides compositions comprising induced pluripotent stem cells (iPSCs) derived from such progenitor cells. Induced pluripotent stem cell progenitors generate iPSCs at high efficiency. In particular embodiments the invention is predicated upon increased expression of an estrogen related receptor and changes in the oxidative and glycolytic pathways.
    Type: Application
    Filed: February 26, 2016
    Publication date: February 15, 2018
    Applicant: Salk Institute for Biological Studies
    Inventors: Ronald EVANS, Michael DOWNES, Yasuyuki KIDA, Teruhisa KAWAMURA, Zong WEI, Ruth T. YU, Annette R. ATKINS
  • Publication number: 20180036377
    Abstract: The method provides methods and compositions for treating metabolic disorders such as impaired glucose tolerance, elevated blood glucose, insulin resistance, dyslipidemia, obesity, and fatty liver.
    Type: Application
    Filed: September 13, 2017
    Publication date: February 8, 2018
    Applicant: Salk Institute for Biological Studies
    Inventors: Johan W. Jonker, Michael Downes, Ronald M. Evans, Jae Myoung Suh
  • Patent number: 9886493
    Abstract: Methods, devices, and systems are disclosed for producing cognitive and/or sensory profiles. In one aspect, a method to provide a cognitive or sensory assessment of a subject includes selecting a profile category from among a cognitive performance profile, a sensory performance profile, and a cognitive and sensory performance profile, presenting a sequence of stimuli to a subject, the sequence of stimuli based on the selected profile category, acquiring physiological signals of the subject before, during, and after the presenting the sequence of stimuli to produce physiological data, and processing the physiological data to generate an information set including one or more quantitative values associated with the selected profile category.
    Type: Grant
    Filed: September 27, 2013
    Date of Patent: February 6, 2018
    Assignees: The Regents of the University of California, The Salk Institute for Biological Studies
    Inventors: Todd Prentice Coleman, Rui Ma, Sanggyun Kim, Cheolsoo Park, Ricardo Gil Da Costa, Raynard Fung, Diego Mesa
  • Patent number: 9885090
    Abstract: Compositions and methods for detecting a cancer in a subject using a recombinant reporter adenovirus are described. In particular, recombinant adenovirus is used to diagnose a cancer in a patient and further used for screening compounds effective in treating the cancer in said patient.
    Type: Grant
    Filed: September 12, 2014
    Date of Patent: February 6, 2018
    Assignee: Salk Institute for Biological Studies
    Inventors: Clodagh O'Shea, Colin Powers
  • Patent number: 9872866
    Abstract: The present disclosure provides compositions that include a nanoparticle and a compound that increases the biological activity of the vitamin D receptor (VDR) (e.g., a VDR agonist), and methods of using such compounds to increase retention or storage of vitamin A, vitamin D, and/or lipids by a cell, such as an epithelial or stellate cell. Such methods can be used to treat or prevent fibrosis.
    Type: Grant
    Filed: October 23, 2015
    Date of Patent: January 23, 2018
    Assignees: Salk Institute for Biological Studies, The University of Sydney
    Inventors: Ning Ding, Michael Downes, Christopher Liddle, Ronald M. Evans
  • Publication number: 20180015057
    Abstract: Provided herein are methods and kits for increasing cardiac contraction, increasing mitochondrial activity, and/or increasing oxphos activity. Such methods include use of therapeutically effective amounts of one or more agents that increases estrogen-related receptor (ERR) ? activity and one or more agents that increases ERR? activity. In some examples, the method further includes administering a therapeutically effective amount of one or more agents that increases mitofusin 1 (Mfn1) activity.
    Type: Application
    Filed: September 19, 2017
    Publication date: January 18, 2018
    Applicant: Salk Institute for Biological Studies
    Inventors: Ronald M. Evans, Liming Pei, Michael Downes, Ruth T. Yu, Annette Atkins
  • Publication number: 20180000768
    Abstract: Disclosed are embodiments of a method of treating or preventing latent autoimmune diabetes of adults (LADA) in a subject. Such embodiments include administering to a subject (e.g., via the gastrointestinal tract) a therapeutically effective amount of one or farnesoid X receptor (FXR) agonist compounds, thereby activating FXR receptors in the intestines, and treating or preventing latent autoimmune diabetes of adults (LADA) in the subject.
    Type: Application
    Filed: September 6, 2017
    Publication date: January 4, 2018
    Applicant: Salk Institute for Biological Studies
    Inventors: Sungsoon Fang, Eiji Yoshihara, Ruth T. Yu, Annette Atkins, Michael Downes, Ronald M. Evans
  • Patent number: 9850319
    Abstract: Isolated monoclonal antibodies and or antigen binding fragments thereof are disclosed herein that specifically bind polypeptides comprising a histidine phosphorylated at N3 (3-pHis). Nucleic acids encoding these antibodies, vectors including these nucleic acids, and host cells transformed with these vectors and nucleic acids are also disclosed. Methods are also disclosed for using these antibodies, such as for detection of polypeptides comprising a histidine phosphorylated at N3 (3-pHis). In some embodiments, the methods can be used to investigate signal transduction pathways.
    Type: Grant
    Filed: July 1, 2015
    Date of Patent: December 26, 2017
    Assignees: Salk Institute for Biological Studies, Sanofi
    Inventors: Tony Hunter, Stephen Rush Fuhs, Jill Meisenhelder, Jacques Mauger, Magda Stankova, Fahad Al-Obeidi, Robert A. Binne
  • Publication number: 20170355740
    Abstract: The present disclosure provides FGF1 mutant proteins having one or more mutations in the heparin binding domain. Such mutants may also have an N-terminal deletion, point mutation(s), or combinations thereof. In some examples, the mutant FGF1 proteins have reduced mitogenic activity. Also provided are nucleic acid molecules that encode such proteins, and vectors and cells that include such nucleic acids. The disclosed FGF1 mutants can reduce blood glucose in a mammal, and in some examples are used to treat a metabolic disorder.
    Type: Application
    Filed: August 21, 2017
    Publication date: December 14, 2017
    Applicant: Salk Institute for Biological Studies
    Inventors: Ronald M. Evans, Michael Downes, Annette Atkins, Ruth T. Yu
  • Publication number: 20170355739
    Abstract: The present disclosure provides FGF1 mutant proteins having one or more mutations in the heparin binding domain. Such mutants may also have an N-terminal deletion, point mutation(s), or combinations thereof. In some examples, the mutant FGF1 proteins have reduced mitogenic activity. Also provided are nucleic acid molecules that encode such proteins, and vectors and cells that include such nucleic acids. The disclosed FGF1 mutants can reduce blood glucose in a mammal, and in some examples are used to treat a metabolic disorder.
    Type: Application
    Filed: August 21, 2017
    Publication date: December 14, 2017
    Applicants: Salk Institute for Biological Studies, The Florida State University Research Foundation, Incorporated
    Inventors: Ronald M. Evans, Michael Downes, Annette Atkins, Ruth T. Yu, Michael Blaber, Xue Xia
  • Publication number: 20170342088
    Abstract: In certain aspects, the invention provides a method for treating a disease or condition in a subject, the method comprising co-administering to a subject in need thereof a therapeutically effective amount of at least one ULK1-inhibiting pyrimidine, and a therapeutically effective amount of an mTOR inhibitor.
    Type: Application
    Filed: August 25, 2015
    Publication date: November 30, 2017
    Applicants: SALK INSTITUTE FOR BIOLOGICAL STUDIES, SANFORD-BURNHAM MEDICAL RESEARCH INSTITUTE, YALE UNIVERSITY
    Inventors: REUBEN J. SHAW, DANIEL F. EGAN, NICHOLAS COSFORD, BENJAMIN TURK, MITCHELL VAMOS, DHANYA RAVEENDRA PANICKAR, MATTHEW CHUN, DOUG SHEFFLER
  • Publication number: 20170291931
    Abstract: The present disclosure provides FGF2 mutant proteins, such as those having an N-terminal deletion, point mutation(s), or combinations thereof, which can reduce blood glucose in a mammal. Thus, the disclosed mutant FGF2 proteins can be used to treat one or more metabolic diseases. In some examples, mutant FGF2 proteins have reduced mitogenic activity. Also provided are nucleic acid molecules that encode such proteins, and vectors and cells that include such nucleic acids. Methods of using the disclosed molecules to reduce blood glucose levels, for example to treat a metabolic disorder are also provided.
    Type: Application
    Filed: June 8, 2017
    Publication date: October 12, 2017
    Applicant: Salk Institute for Biological Studies
    Inventors: Ronald M. Evans, Michael Downes, Annette Atkins, Jae Myoung Suh, Ruth T. Yu